Literature DB >> 18649131

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.

T Byrski1, T Huzarski, R Dent, J Gronwald, D Zuziak, C Cybulski, J Kladny, B Gorski, J Lubinski, S A Narod.   

Abstract

BACKGROUND: Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy.
METHODS: The excised breast tissue and lymph nodes were examined for the presence of residual disease.
RESULTS: Pathologic complete response was observed in nine patients (90%).
CONCLUSIONS: Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18649131     DOI: 10.1007/s10549-008-0128-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  111 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 2.  Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.

Authors:  Marina Pajic; Christopher J Scarlett; David K Chang; Robert L Sutherland; Andrew V Biankin
Journal:  Hum Genet       Date:  2011-04-23       Impact factor: 4.132

3.  How do I treat "triple-negative" disease.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Curr Treat Options Oncol       Date:  2011-12

4.  AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.

Authors:  Christoph Thomssen; Anton Scharl; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2011-08-30       Impact factor: 2.860

Review 5.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 6.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

Review 7.  The role of BRCA mutation testing in determining breast cancer therapy.

Authors:  Alison H Trainer; Craig R Lewis; Kathy Tucker; Bettina Meiser; Michael Friedlander; Robyn L Ward
Journal:  Nat Rev Clin Oncol       Date:  2010-11-09       Impact factor: 66.675

Review 8.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

Review 9.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

10.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Authors:  Melinda L Telli; Kirsten M Timms; Julia Reid; Bryan Hennessy; Gordon B Mills; Kristin C Jensen; Zoltan Szallasi; William T Barry; Eric P Winer; Nadine M Tung; Steven J Isakoff; Paula D Ryan; April Greene-Colozzi; Alexander Gutin; Zaina Sangale; Diana Iliev; Chris Neff; Victor Abkevich; Joshua T Jones; Jerry S Lanchbury; Anne-Renee Hartman; Judy E Garber; James M Ford; Daniel P Silver; Andrea L Richardson
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.